Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...

To understand how the Mayo Clinic became a superior healthcare brand, I talked with Leonard Berry, PhD, to understand their ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...